How long does polivy stay in the body?

How long does polivy stay in the body?

Polivy (polatuzumab vedotin) is an antibody-drug conjugate targeting CD79b on B-cells. Its payload stays bound to microtubules after delivery, disrupting cell division. The antibody portion follows typical IgG1 kinetics with a half-life of around 12 days, but the small-molecule payload MMAE gets released gradually and shows a longer terminal half-life of about 3–4 days.

Why does clearance take so long?

Polivy’s clearance follows nonlinear pharmacokinetics at clinical doses. Nonlinearity means the rate of elimination slows as plasma levels rise, so when patients receive 1.8 mg/kg every 21 days, the area under the curve grows more than expected. The drug also distributes widely into tissues, wide distribution explains the extended presence.

How does this time presence affect dosing?

The 21-day dosing interval matches the antibody’s clearance rate. The combination regimen with bendamustine and rituximab keeps plasma levels above the threshold needed to kill target cells during each cycle. Plasma levels fall to below quantifiable limits after several half-lives, but tissue-bound payload remains detectable weeks later.

What happens if a patient misses a cycle?

A single missed cycle allows plasma levels to drop to about 10 percent of target. When the missing cycle is filled at the 21-day gap, the new dose reaches the gewollte level quickly, still within the time frame that keeps the drug effective against diffuse large B-cell lymphoma cells.

When does the patent expire?

The composition-of-matter patent covering polatuzumab vedotin expires in 2030 in the US.